MNKD ▲ +2.4% - MannKind Corporation $MNKD - MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management MannKind rose 2.4% on news of a licensing and collaboration agreement with Rose Pharma to co-develop an inhaled GLP-1 therapy for weight management, adding a potential revenue stream in the competitive weight-loss drug market through its inhalation platform technology. 09-SEP-2026 06:30 AM ET